Real‐World Efficacy and Safety of Dupilumab for Atopic Dermatitis in the Israeli Population

L.S. has received fees as an advisory board member from Sanofi, AbbVie, Pfizer, and Eli Lilly; served as an investigator for Sanofi, AbbVie, Pfizer, Eli Lilly, Amgen, Shulov Innovative Science, and Seanergy. All unrelated to this study. D.B. served as an investigator for Sanofi, AbbVie, Amgen, and Shulov Innovative Science. Other authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.